Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001104659-26-016498·CITADEL ADVISORS LLC
Schedule 13G ownership disclosure
Lexeo Therapeutics Inc
Common Stock ($0.0001 par value) (the "Shares") · CUSIP: 52886X107
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Citadel Advisors LLC
Shares: 5,405,269.00 · Class: 7.2%
- Citadel Advisors Holdings LP
Shares: 5,405,269.00 · Class: 7.2%
- Citadel GP LLC
Shares: 5,405,269.00 · Class: 7.2%
- Citadel Securities LLC
Shares: 6,600.00 · Class: 0.0%
- Citadel Securities Group LP
Shares: 92,950.00 · Class: 0.1%
- Citadel Securities GP LLC
Shares: 92,950.00 · Class: 0.1%
- Kenneth Griffin
Shares: 5,498,219.00 · Class: 7.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-26-016498
- Form type
- SCHEDULE 13G/A
- Filer
- CITADEL ADVISORS LLC
- CIK
- CIK 1423053
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership